Chronic myeloid leukemia: Current perspectives

Clinics in Laboratory Medicine

Volumn 31, Issue 4, 2011, Pages 687-698

  Zhang, Yanming ^a,b   Rowley, Janet D ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

ABL1; BCR; CML; Cytogenetics; FISH; T(9; 22)

Indexed keywords

BCR ABL PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MYC PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

AUTOPHOSPHORYLATION; BLEEDING; BLOOD ANALYSIS; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW EXAMINATION; BONE PAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COPY NUMBER VARIATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG BINDING; DRUG INHIBITION; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUNCTION; GENE FUSION; GENE IDENTIFICATION; GENETIC TRANSFORMATION; GENETIC VARIABILITY; HEMATOPOIETIC CELL; HUMAN; LEUKEMOGENESIS; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHADENOPATHY; METAPHASE; MYELOPROLIFERATIVE DISORDER; ONSET AGE; OVERALL SURVIVAL; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SPLENOMEGALY; SWEATING; TREATMENT FAILURE; TREATMENT RESPONSE; WEIGHT REDUCTION; Y CHROMOSOME;

CYTOGENETIC ANALYSIS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME;

EID: 82355184542     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2011.08.012     Document Type: Review

References (43)

1. Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340:1330-1340.
2. Swerdlow S.H., Campo E., Harris N., et al. WHO classification of tumors of hematopoietic and lymphoid tissue 2008, IARC Press, Lyon (France). 4th edition.
3. Melo J.V. The molecular biology of chronic myeloid leukemia. Leukemia 1996, 10:751-756.
4. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497-1499.
5. Rowley J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
6. de Klein A., van Kessel A.G., Grosveld G., et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300:765-767.
7. Heisterkamp N., Stam K., Groffen J., et al. Structural organization of the BCR gene and its role in the Ph' translocation. Nature 1985, 315:758-761.
8. Groffen J., Stephenson J.R., Heisterkamp N., et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
9. Shtivelman E., Lifshitz B., Gale R.P., et al. Fused transcript of ABL1 and BCR genes in chronic myelogenous leukaemia. Nature 1985, 315:550-554.
10. Grosveld G., Verwoerd T., van Agthoven T., et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-ABL1 transcript. Mol Cell Biol 1986, 6:607-616.
11. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the ABL1 tyrosine kinase on the growth of BCR-ABL1 position cells. Nat Med 1996, 2:561-566.
12. Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002, 107:76-94.
13. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
14. Sokal J.E., Gomez G.A., Baccarani M., et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988, 72:294-298.
15. Lima L., Bernal-Mizrachi L., Saxe D., et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with Imatinib, second-line agents, and beyond. Cancer 2011, 117:1245-1252.
16. Landstrom A.P., Ketterling R.P., Knudson R.A., et al. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL1 fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma 2006, 47:2055-2061.
17. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
18. Drucker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving in Imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
19. La Rosée P., Hochhaus A. Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 2010, 17:91-96.
20. Daley G.O., van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/ABL1 gene of the Philadelphia chromosome. Science 1990, 247:824-830.
21. Maciejewaski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematological malignancies. Blood 2008, 112:965-974.
22. Huh J., Jung C.W., Kim J.W., et al. Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after Imatinib therapy in chronic myeloid leukemia. Ann Hematol 2011, 90(11):1255-1264.
23. Brazma D., Grace C., Howard J., et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Gene Chrom Cancer 2007, 46:1039-1050.
24. Nacheva E.P., Brazma D., Virgili A., et al. Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics 2010, 11:41-52.
25. Gondek L.P., Dunbar A.J., Szpurka H., et al. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLOS One 2007, 2:e1225.
26. Hosoya N., Sanada M., Nannya Y., et al. Genome-wide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Gene Chrom Cancer 2006, 45:482-494.
27. Zhang Y., Rowley J.D. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair 2006, 5:1282-1297.
28. Huntly B.J., Bench A.J., Delabesse E., et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL1-BCR expression, elevated BCR-ABL1 levels, or karyotypic instability. Blood 2002, 99:4547-4553.
29. Castagnetti F., Testoni N., Luatti S., et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with Imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010, 28:2748-2754.
30. Sinclair P.B., Nacheva E.P., Leversha M., et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000, 95:738-743.
31. Huntly B.J., Reid A.G., Bench A.J., et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001, 98:1732-1738.
32. Kreil S., Pfirrmann M., Haferlach C., et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007, 110:1283-1290.
33. Huntly B.J., Bench A., Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003, 102:1160-1168.
34. Huntly B.J., Guilhot F., Reid A.G., et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003, 102:2205-2212.
35. Fourouclas N., Campbell P.J., Bench A.J., et al. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukaemia. Haematologica 2006, 91:952-955.
36. de la Fuente J., Merx K., Steer E.J., et al. ABL1-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001, 98:2879-2880.
37. Melo J.V., Gordon D.E., Cross N.C., et al. The ABL1-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993, 81:158-165.
38. Bumm T., Muller C., Al-Ali H.K., et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to Imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003, 101:1941-1949.
39. Jabbour E., Kantarjian H.M., Abruzzo L.V., et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during Imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007, 110:2991-2995.
40. Sun J., Yin C., Cui W., et al. Chromosome 20q deletion. A recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission. Hematopathol 2011, 135:391-397.
41. Storlazzi C., Specchia G., Anelli L., et al. Break-point characterization of der(9) deletions in chronic myeloid leukemia patients. Gene Chrom Cancer 2002, 35:271-276.
42. Oehler V.G., Yeung K.Y., Choi Y.E., et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009, 114:3292-3298.
43. Chaubey A., Karanti S., Rai D., et al. microRNAs and deletion of the derivative chromosome 9 in chronic myeloid leukemia. Leukemia 2009, 23:186-188.